Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer

被引：1
|
作者：
Mardani, Mahta
Noordeen, Suleyman
Clifton, Katherine
Ma, Cynthia
Luo, Jingqin
Xi, Jing
Bagegni, Nusayba
Ademuyiwa, Foluso
Suresh, Rama
Frith, Ashley
Davis, Andrew
Bose, Ron
Peterson, Lindsay
Thomas, Shana
Tao, Yu
Kobayashi, Takayuki
Xiang, Jingyu
Xu, Yalin
Su, Xinming
Weilbaecher, Katherine
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
    Visani, Luca
    Livi, Lorenzo
    Ratosa, Ivica
    Orazem, Miha
    Ribnikar, Domen
    Saieva, Calogero
    Becherini, Carlotta
    Salvestrini, Viola
    Scoccimarro, Erika
    Valzano, Marianna
    Cerbai, Cecilia
    Desideri, Isacco
    Bernini, Marco
    Orzalesi, Lorenzo
    Nori, Jacopo
    Bianchi, Simonetta
    Morandi, Andrea
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2022, 177 : 40 - 45
  • [22] Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors
    Meegdes, Marissa
    van der Velde, Marleen G. A. M.
    Geurts, Sandra M. E.
    van Kats, Maartje A. C. E.
    Dercksen, M. Wouter
    Tjan-Heijnen, Vivianne C. G.
    JOURNAL OF CHEMOTHERAPY, 2024, 36 (04) : 343 - 350
  • [23] Evaluation and optimization of treatment for patients with metastatic breast cancer and receiving CDK4/6-inhibitors
    Henze, F.
    Hester, A.
    Koenig, A.
    Harbeck, N.
    Wuerstlein, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S34 - S35
  • [24] CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety
    Wekking, Demi
    Lambertini, Matteo
    Dessi, Mariele
    Denaro, Nerina
    Bardanzellu, Fabio
    Garrone, Ornella
    Scartozzi, Mario
    Solinas, Cinzia
    SEMINARS IN ONCOLOGY, 2023, 50 (06) : 131 - 139
  • [25] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
    Cobec, Ionut Marcel
    Moleriu, Lavinia
    Moatar, Aurica Elisabeta
    Rempen, Andreas
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
  • [26] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
    Barroso-Sousa, Romualdo
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    BREAST CARE, 2016, 11 (03) : 167 - 173
  • [27] RETRACTED: Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC). (Retracted Article)
    Raimondi, Lucrezia
    Di Benedetto, Laura
    Naso, Giuseppe
    Raimondi, Filippo Maria
    Di Rocco, Arianna
    Giaconi, Laura
    Lazzeroni, Rachele
    Spinelli, Gian Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] SBRT with CDK4/6 inhibitors for oligorecurrent/oligoprogressive breast cancer patients
    Ippolito, E.
    Onorati, E.
    Greco, C.
    Fiore, M.
    Silipigni, S.
    Matteucci, P.
    Cerasani, L.
    Carrafiello, S.
    Palumbo, V.
    Ramella, S.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1298 - S1298
  • [29] Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
    Hanna, Paul E.
    Strohbehn, Ian A.
    Moreno, Daiana
    Harden, Destiny
    Seethapathy, Rituvanthikaa
    Sawtell, Rani
    Wang, Qiyu
    Ouyang, Tianqi
    Katz-Agranov, Nurit
    Dinulos, James
    Wander, Seth A.
    Gupta, Shruti
    Sise, Meghan E.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [30] Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
    Paul E. Hanna
    Ian A. Strohbehn
    Daiana Moreno
    Destiny Harden
    Rituvanthikaa Seethapathy
    Rani Sawtell
    Qiyu Wang
    Tianqi Ouyang
    Nurit Katz-Agranov
    James Dinulos
    Seth A. Wander
    Shruti Gupta
    Meghan E. Sise
    npj Breast Cancer, 9
12345